• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Microbiol Infect . The kinetics of viral load and antibodiesto SARS-CoV-2

tetano

Editor, Senior Moderator
Clin Microbiol Infect


. 2020 Sep 5;S1198-743X(20)30527-9.
doi: 10.1016/j.cmi.2020.08.043. Online ahead of print.
The kinetics of viral load and antibodiesto SARS-CoV-2


Jiufeng Sun[SUP] 1 [/SUP], Xi Tang[SUP] 2 [/SUP], Ru Bai[SUP] 3 [/SUP], Chumin Liang[SUP] 1 [/SUP], Lilian Zeng[SUP] 1 [/SUP], Huifang Lin[SUP] 1 [/SUP], Runyu Yuan[SUP] 1 [/SUP], Pingping Zhou[SUP] 1 [/SUP], Xuhe Huang[SUP] 1 [/SUP], Qianlin Xiong[SUP] 1 [/SUP], Jinju Peng[SUP] 1 [/SUP], Fengfu Cui[SUP] 1 [/SUP], Bixia Ke[SUP] 4 [/SUP], Juan Su[SUP] 4 [/SUP], Zhe Liu[SUP] 1 [/SUP], Jing Lu[SUP] 1 [/SUP], Junzhang Tian[SUP] 3 [/SUP], Ruilin Sun[SUP] 5 [/SUP], Changwen Ke[SUP] 6 [/SUP]



Affiliations

Abstract

Objectives: To understand persistence of the virus in body fluids and immune response of infected host to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an agent of coronavirus disease 2019 (COVID-19).
Methods: We determined the kinetics of viral load in several body fluids through real time reverse transcription polymerase chain reaction (rRT-PCR), serum antibodies of IgA, IgG and IgM by enzyme linked immunosorbent assay (ELISA), and neutralizing antibodies by microneutralization assay in 35 COVID-19 cases from two hospitals in Guangdong, China.
Results: We found higher viral loads and prolonged shedding of virus RNA in severe cases of COVID-19 in nasopharyngeal (1.3?10[SUP]6[/SUP] vs 6.4?10[SUP]4[/SUP], p<0.05; 7∼8w) and throat (6.9?10[SUP]6[/SUP] vs 2.9?10[SUP]5[/SUP], p<0.05; 4∼5w), while comparable in sputum samples (5.5?10[SUP]6[/SUP] vs 0.9?10[SUP]6[/SUP], p<0.05; 4∼5w). Viraemia was rarely detected (2.8%, n=1/35). We detected early seroconversion of IgA and IgG at 1[SUP]st[/SUP] week after illness onset (day 5, 5.7%, n=2/35). Neutralizing antibodies were produced in the second week, and observed in all 35 included cases after 3[SUP]rd[/SUP] week illness onset. The levels of neutralizing antibodies correlated with IgG (r[SUB]s[/SUB]=0.85, p<0.05; kappa=0.85) and IgA (r[SUB]s[/SUB]=0.64, p<0.05; kappa=0.61) in severe, but not mild cases (IgG, r[SUB]s[/SUB]=0.42, kappa=0.33; IgA, r[SUB]s[/SUB]=0.32, kappa=0.22). No correlation with IgM in either severe (r[SUB]s[/SUB]=0.17, kappa=0.06) or mild cases (r[SUB]s[/SUB]=0.27, kappa=0.15) was found.
Conclusions: We revealed a prolonged shedding of virus RNA in upper respiratory tract, and evaluated the consistency production of IgG, IgA, IgM and neutralizing antibodies in COVID-19 cases.

Keywords: COVID-19; IgA; IgG; IgM; SARS-CoV-2; neutralizing antibodies; viral load.
 
Back
Top Bottom